Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 94 R&D pipeline: Haemophilia and growth disorders Product/project Type Indication N9-GP (NN7999)¹ GlycoPEGylated long-acting rFIX Haemophilia B N8-GP (NN7088) GlycoPEGylated long-acting rFVIII Haemophilia A Concizumab (NN7415) Monoclonal anti-TFPI Haemophilia A, B and with inhibitors Somapacitan (NN8640) 2 Once-weekly human growth hormone Growth disorder Status (phase) 1 2 3 Filed Appr. 1 Submitted to the to the European Medicines Agency in January 2016 and the US Food and Drug Administration in May 2016; 2 Phase 3 completed in Adult Growth Hormone Deficiency (AGHD) changing diabetes novo nordisk

View entire presentation